173 related articles for article (PubMed ID: 22228276)
1. The value of cyclooxygenase-2 expression in differentiating between early melanomas and histopathologically difficult types of benign human skin lesions.
Kuźbicki Ł; Lange D; Strączyńska-Niemiec A; Chwirot BW
Melanoma Res; 2012 Feb; 22(1):70-6. PubMed ID: 22228276
[TBL] [Abstract][Full Text] [Related]
2. Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours.
Chwirot BW; Kuźbicki Ł
Melanoma Res; 2007 Jun; 17(3):139-45. PubMed ID: 17505259
[TBL] [Abstract][Full Text] [Related]
3. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
[TBL] [Abstract][Full Text] [Related]
4. Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression.
Kuźbicki L; Sarnecka A; Chwirot BW
Melanoma Res; 2006 Feb; 16(1):29-36. PubMed ID: 16432453
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase-2 immunohistochemistry in human melanoma: differences between results obtained with different antibodies.
Kuzbicki L; Lange D; Chwirot BW
Melanoma Res; 2009 Oct; 19(5):294-300. PubMed ID: 19543125
[TBL] [Abstract][Full Text] [Related]
6. Spitz naevi may express components of the plasminogen activation system.
Ferrier CM; Van Geloof WL; Straatman H; Van De Molengraft FJ; Van Muijen GN; Ruiter DJ
J Pathol; 2002 Sep; 198(1):92-9. PubMed ID: 12210068
[TBL] [Abstract][Full Text] [Related]
7. Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas.
Fröhlich E; Mack AF; Garbe C; Klessen C
Br J Dermatol; 2005 Dec; 153(6):1159-65. PubMed ID: 16307652
[TBL] [Abstract][Full Text] [Related]
8. WT1 as a complementary marker of malignant melanoma: an immunohistochemical study of whole sections.
Wilsher M; Cheerala B
Histopathology; 2007 Nov; 51(5):605-10. PubMed ID: 17927581
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of tumour-infiltrating CD4+CD25+FOXP3+ regulatory T cells in human cutaneous benign and atypical naevi, melanomas and melanoma metastases.
Mourmouras V; Fimiani M; Rubegni P; Epistolato MC; Malagnino V; Cardone C; Cosci E; Nisi MC; Miracco C
Br J Dermatol; 2007 Sep; 157(3):531-9. PubMed ID: 17596146
[TBL] [Abstract][Full Text] [Related]
10. Different patterns of expression of the erbB family of receptor tyrosine kinases in common nevi, dysplastic nevi, and primary malignant melanomas: an immunohistochemical study.
Feinmesser M; Veltman V; Morgenstern S; Tobar A; Gutman H; Kaganovsky E; Tzabari C; Sulkes J; Okon E
Am J Dermatopathol; 2010 Oct; 32(7):665-75. PubMed ID: 20559114
[TBL] [Abstract][Full Text] [Related]
11. S100 protein, neurone specific enolase, and nuclear DNA content in Spitz naevus.
Rode J; Williams RA; Jarvis LR; Dhillon AP; Jamal O
J Pathol; 1990 May; 161(1):41-5. PubMed ID: 2370597
[TBL] [Abstract][Full Text] [Related]
12. [Comparative study of HMB-45 monoclonal antibody uptake on various benign and malignant melanocytic lesions].
Lampert A; Thomine E; Lauret P; Hemet J
Ann Pathol; 1993; 13(2):100-7. PubMed ID: 8363667
[TBL] [Abstract][Full Text] [Related]
13. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic and prognostic role of galectin 3 expression in cutaneous melanoma.
Abdou AG; Hammam MA; Farargy SE; Farag AG; El Shafey EN; Farouk S; Elnaidany NF
Am J Dermatopathol; 2010 Dec; 32(8):809-14. PubMed ID: 20885286
[TBL] [Abstract][Full Text] [Related]
15. Presence of cytogenetic abnormalities in Spitz naevi: a diagnostic challenge for fluorescence in-situ hybridization analysis.
Martin V; Banfi S; Bordoni A; Leoni-Parvex S; Mazzucchelli L
Histopathology; 2012 Jan; 60(2):336-46. PubMed ID: 22211292
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of cyclooxygenase-2 (COX-2) in oral nevi and melanoma.
de Souza do Nascimento J; Carlos R; Delgado-Azañero W; Mosqueda Taylor A; de Almeida OP; Romañach MJ; de Andrade BA
J Oral Pathol Med; 2016 Jul; 45(6):440-3. PubMed ID: 26608958
[TBL] [Abstract][Full Text] [Related]
17. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
Fullen DR; Zhu W; Thomas D; Su LD
J Cutan Pathol; 2005 Nov; 32(10):680-4. PubMed ID: 16293180
[TBL] [Abstract][Full Text] [Related]
18. Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas.
Glaessl A; Bosserhoff AK; Buettner R; Hohenleutner U; Landthaler M; Stolz W
Arch Dermatol Res; 1999; 291(2-3):81-7. PubMed ID: 10195394
[TBL] [Abstract][Full Text] [Related]
19. Pitfalls in the evaluation of melanocytic lesions.
Brenn T
Histopathology; 2012 Apr; 60(5):690-705. PubMed ID: 22176022
[TBL] [Abstract][Full Text] [Related]
20. COX-1 and COX-2 expression in canine cutaneous, oral and ocular melanocytic tumours.
Pires I; Garcia A; Prada J; Queiroga FL
J Comp Pathol; 2010; 143(2-3):142-9. PubMed ID: 20207364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
